• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Hinge Health Inc.

    3/3/26 5:07:41 PM ET
    $HNGE
    EDP Services
    Technology
    Get the next $HNGE alert in real time by email
    S-8 1 tm267248d1_s8.htm FORM S-8

     

    As filed with the U.S. Securities and Exchange Commission on March 3, 2026

    Registration No. 333-

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

    HINGE HEALTH, INC.

    (Exact Name of Registrant as Specified in Its Charter)

     

    Delaware 81-1884841
    (State or Other Jurisdiction of (I.R.S. Employer
    Incorporation or Organization) Identification No.)

     

    455 Market Street, Suite 700

    San Francisco, California 94105

    (Address of Principal Executive Offices) (Zip Code)

     

    Hinge Health, Inc. 2025 Incentive Award Plan

    Hinge Health, Inc. 2025 Employee Stock Purchase Plan

    (Full Title of the Plans)

     

    Daniel Perez

    Chief Executive Officer

    Hinge Health, Inc.

    455 Market Street, Suite 700 

    San Francisco, California 94105

    (Name and Address of Agent for Service)

    (415) 726-2206

    (Telephone Number, including area code, of agent for service)

     

    Please send copies of all communications to:

     

    Ran Ben-Tzur, Esq.

    Amanda Rose, Esq.

    Jen Hitchcock, Esq.

    Fenwick & West LLP

    730 Arizona Ave, 1st Floor

    Santa Monica, California 90401

    (415) 875-2300

    Mahnaz K. Dodge

    Lead Counsel

    Hinge Health, Inc.

    455 Market Street, Suite 700

    San Francisco, California 94105

    (415) 726-2206

     

    Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ¨   Accelerated filer ¨
    Non-accelerated filer x   Smaller reporting company ¨
          Emerging growth company x
             
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     

     

     

     

    REGISTRATION OF ADDITIONAL SHARES

    PURSUANT TO GENERAL INSTRUCTION E

     

    Hinge Health, Inc. (the “Registrant”) is filing this Registration Statement with the Securities and Exchange Commission (the “Commission”) to register (a) 4,087,657 additional shares of the Registrant’s Class A common stock (“Class A Common Stock”) available for issuance under the Registrant’s 2025 Incentive Award Plan (the “2025 Plan”) pursuant to the provision of the 2025 Plan providing for an annual automatic increase in the number of shares reserved for issuance under the 2025 Plan equal to 5% of the aggregate number of shares of all classes of the Registrant’s common stock outstanding (on an as-converted basis) and (b) 817,531 additional shares of Class A Common Stock available for issuance under the Registrant’s 2025 Employee Stock Purchase Plan (the “2025 ESPP”) pursuant to the provision of the 2025 ESPP providing for an annual automatic increase in the number of shares reserved for issuance under the 2025 ESPP equal to 1% of the aggregate number of all classes of the Registrant’s common stock outstanding (on an as-converted basis).

     

    In accordance with General Instruction E of Form S-8, and only with respect to the Class A Common Stock issuable under the 2025 Plan and 2025 ESPP, this Registration Statement hereby incorporates by reference the contents of the Registrant’s Registration Statement on Form S-8 filed with the Commission on May 22, 2025 (Registration No. 333-287497), to the extent not superseded hereby.

     

    In accordance with the instructional note of Part I of Form S-8 as promulgated by the Commission, the information specified by Part I of Form S-8 has been omitted from this Registration Statement.

     

    PART II

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3. Incorporation of Documents by Reference.

     

    The following documents filed by the Registrant with the Commission pursuant to the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended (the “Exchange Act”) are incorporated herein by reference:

     

    (a)  the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Commission on March 3, 2026, pursuant to Section 13(a) of the Exchange Act;

     

    (b)  all other reports filed pursuant to Section 13(a) or 15(d) of the Exchange Act since the end of the fiscal year covered by the Registrant’s Annual Report on Form 10-K referred to in (a) above; and

     

    (c) the description of the Registrant’s Class A common stock contained in the Registrant’s registration statement on Form 8-A (File No. 001-42657) filed with the Commission on May 19, 2025, under Section 12(b) of the Exchange Act, as updated by the description of the Registrant’s registered securities contained in Exhibit 4.3 to the Registrant’s Annual Report on Form 10-K referred to in (a) above, including any amendment or report filed for the purpose of updating such description.

     

    All reports, documents and definitive proxy or information statements filed by the Registrant pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act subsequent to the filing of this Registration Statement and prior to the filing of a post-effective amendment, which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement and to be a part hereof from the date of filing such documents, except as to documents or information deemed to have been furnished and not filed in accordance with the rules of the Commission. Unless expressly incorporated into this Registration Statement, a report deemed to be furnished but not filed on Form 8-K prior or subsequent to the date hereof shall not be incorporated by reference into this Registration Statement. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained in any subsequently filed document which also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

     

    Item 5. Interests of Named Experts and Counsel

     

    Not applicable.

     

     

     

     

    Item 8. Exhibits.

     

    The following exhibits are filed herewith or incorporated by reference:

     

    Exhibit       Incorporated by Reference   Filed
    Number   Exhibit Description   Form   File No.   Exhibit   Filing Date   Herewith
                             
    4.1   Amended and Restated Certificate of Incorporation   8-K   001-42657   3.1   05/23/2025    
                             
    4.2   Amended and Restated Bylaws   8-K   001-42657   3.2   05/23/2025    
                             
    4.3   Form of Class A Common Stock Certificate   S-1/A   333-285682   4.2   04/07/2025    
                             
    5.1   Opinion of Fenwick & West LLP                   X
                             
    23.1   Consent of Independent Registered Public Accounting Firm                   X
                             
    23.2   Consent of Fenwick & West LLP (contained in Exhibit 5.1)                   X
                             
    24.1   Power of Attorney (included on signature page to this Registration Statement)                   X
                             
    99.1   2025 Incentive Award Plan, and forms of award agreements   S-1/A   333-285682   10.2   05/16/2025    
                             
    99.2   2025 Employee Stock Purchase Plan, and forms of award agreements   S-1/A   333-285682   10.3   05/16/2025    
                             
    107.1   Filing Fee Table                   X

      

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in San Francisco, California, on this 3rd day of March, 2026.

     

      HINGE HEALTH, INC.
       
      By:
      /s/ Daniel Perez
      Daniel Perez
      Chief Executive Officer

     

    POWER OF ATTORNEY

     

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Daniel Perez and James Budge, and each of them, as his or her true and lawful attorney-in-fact and agent with full power of substitution, for him or her in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his or her substitute, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the date indicated.

     

    Signature Title Date
    /s/ Daniel Perez

    Chief Executive Officer and Director

    (Principal Executive Officer)

    March 3, 2026
    Daniel Perez  
         
    /s/ James Budge

    Chief Financial Officer

    (Principal Financial and Accounting Officer)

    March 3, 2026
    James Budge  
         
    /s/ Kristina Leslie Director March 3, 2026
    Kristina Leslie    
         
    /s/ Gabriel Mecklenburg Director March 3, 2026
    Gabriel Mecklenburg    
         
    /s/ Elliott Robinson Director March 3, 2026
    Elliott Robinson    
         
    /s/ Teddie Wardi Director March 3, 2026
    Teddie Wardi    

     

     

     

    Get the next $HNGE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HNGE

    DatePrice TargetRatingAnalyst
    1/9/2026$68.00Overweight
    Wells Fargo
    9/5/2025$56.00Neutral
    Robert W. Baird
    7/14/2025$58.00Mkt Outperform
    Citizens JMP
    6/16/2025Outperform
    William Blair
    6/16/2025$48.00Buy
    Truist
    6/16/2025$48.00Buy
    Stifel
    6/16/2025$45.00Outperform
    Raymond James
    6/16/2025$41.00Overweight
    Piper Sandler
    More analyst ratings

    $HNGE
    SEC Filings

    View All

    SEC Form S-8 filed by Hinge Health Inc.

    S-8 - Hinge Health, Inc. (0001673743) (Filer)

    3/3/26 5:07:41 PM ET
    $HNGE
    EDP Services
    Technology

    SEC Form 10-K filed by Hinge Health Inc.

    10-K - Hinge Health, Inc. (0001673743) (Filer)

    3/3/26 4:11:33 PM ET
    $HNGE
    EDP Services
    Technology

    SEC Form 144 filed by Hinge Health Inc.

    144 - Hinge Health, Inc. (0001673743) (Subject)

    2/23/26 4:30:05 PM ET
    $HNGE
    EDP Services
    Technology

    $HNGE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President Pursley James covered exercise/tax liability with 5,127 shares, decreasing direct ownership by 0.68% to 747,104 units (SEC Form 4)

    4 - Hinge Health, Inc. (0001673743) (Issuer)

    3/3/26 5:27:08 PM ET
    $HNGE
    EDP Services
    Technology

    Chief Financial Officer Budge James covered exercise/tax liability with 7,699 shares, decreasing direct ownership by 2% to 412,433 units (SEC Form 4)

    4 - Hinge Health, Inc. (0001673743) (Issuer)

    3/3/26 5:25:44 PM ET
    $HNGE
    EDP Services
    Technology

    President Pursley James sold $589,984 worth of shares (15,000 units at $39.33), decreasing direct ownership by 2% to 752,231 units (SEC Form 4)

    4 - Hinge Health, Inc. (0001673743) (Issuer)

    2/24/26 4:21:39 PM ET
    $HNGE
    EDP Services
    Technology

    $HNGE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Hinge Health reports fourth quarter and full year 2025 financial results

    Hinge Health, Inc. (NYSE:HNGE) today announced record financial results for the quarter and year ended December 31, 2025. "We closed out the year with an exceptional quarter and a strong selling season, driving our highest win rates to date and greatest number of eligible lives added in any year," said Daniel Perez, Co-Founder and CEO, Hinge Health. "Our commercial momentum, combined with expanding margins and strong cash generation, gives us confidence in our ability to continue automating care delivery, sustain our position as a leader in digital musculoskeletal care, and drive attractive growth and increased margins in 2026." Fourth Quarter 2025 Financial Highlights: Revenue incre

    2/10/26 4:05:00 PM ET
    $HNGE
    EDP Services
    Technology

    Hinge Health's 2026 State of Musculoskeletal Care Report reveals stark gaps in traditional care

    Today, Hinge Health (NYSE:HNGE) released its sixth annual State of Musculoskeletal (MSK) Care Report, revealing how today's fragmented healthcare system leaves many people unsure how to pursue treatment for MSK pain. Hinge Health surveyed 1,000 people living with MSK pain alongside 295 healthcare providers to understand the systemic challenges and opportunities for industry-wide improvements. The dual-perspective survey – along with real patient and provider stories – maps a clear path to more effective, unified care. "While Hinge Health's digital physical therapy program has dramatically increased access, MSK care still feels like a maze for too many people," said Dr. Jeffrey Krauss, MD,

    1/15/26 11:00:00 AM ET
    $HNGE
    EDP Services
    Technology

    Hinge Health to announce fourth quarter and full year 2025 financial results on February 10, 2026

    Hinge Health, Inc. (NYSE:HNGE) announced today that it will report its financial results for the fourth quarter and full year 2025 after the U.S. financial markets close on Tuesday, February 10, 2026. Hinge Health will also host an earnings conference call to discuss its results and guidance at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) the same day. The live audio webcast of the earnings conference call will be available on the Hinge Health Investor Relations website at ir.hingehealth.com. A replay of the webcast will be available on the same website shortly after its completion. About Hinge Health Hinge Health is focused on scaling and automating the delivery of health care, st

    1/14/26 9:00:00 AM ET
    $HNGE
    EDP Services
    Technology

    $HNGE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wells Fargo initiated coverage on Hinge Health with a new price target

    Wells Fargo initiated coverage of Hinge Health with a rating of Overweight and set a new price target of $68.00

    1/9/26 9:05:22 AM ET
    $HNGE
    EDP Services
    Technology

    Robert W. Baird initiated coverage on Hinge Health with a new price target

    Robert W. Baird initiated coverage of Hinge Health with a rating of Neutral and set a new price target of $56.00

    9/5/25 7:59:54 AM ET
    $HNGE
    EDP Services
    Technology

    Citizens JMP initiated coverage on Hinge Health with a new price target

    Citizens JMP initiated coverage of Hinge Health with a rating of Mkt Outperform and set a new price target of $58.00

    7/14/25 8:51:47 AM ET
    $HNGE
    EDP Services
    Technology

    $HNGE
    Financials

    Live finance-specific insights

    View All

    Hinge Health to announce fourth quarter and full year 2025 financial results on February 10, 2026

    Hinge Health, Inc. (NYSE:HNGE) announced today that it will report its financial results for the fourth quarter and full year 2025 after the U.S. financial markets close on Tuesday, February 10, 2026. Hinge Health will also host an earnings conference call to discuss its results and guidance at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) the same day. The live audio webcast of the earnings conference call will be available on the Hinge Health Investor Relations website at ir.hingehealth.com. A replay of the webcast will be available on the same website shortly after its completion. About Hinge Health Hinge Health is focused on scaling and automating the delivery of health care, st

    1/14/26 9:00:00 AM ET
    $HNGE
    EDP Services
    Technology

    Hinge Health to announce third quarter 2025 financial results on November 4, 2025

    Hinge Health, Inc. (NYSE:HNGE) announced today that it will report its financial results for the quarter ended September 30, 2025, after the U.S. markets close on Tuesday, November 4, 2025. Hinge Health will also host an earnings conference call to discuss its results and guidance at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) the same day. The live audio webcast of the earnings conference call will be available on the Hinge Health Investor Relations website at ir.hingehealth.com. A replay of the webcast will be available on the same website shortly after its completion. About Hinge Health Hinge Health is focused on scaling and automating the delivery of health care, starting with

    10/1/25 5:00:00 PM ET
    $HNGE
    EDP Services
    Technology

    Hinge Health Reports Second Quarter 2025 Financial Results

    Hinge Health, Inc. (NYSE:HNGE) today announced financial results for the second quarter ended June 30, 2025. "In Q2 we delivered year-over-year revenue growth of 55% and a strong free cash flow margin, underlining the market's embrace of our AI-powered platform," said Daniel Perez, Co-Founder and CEO, Hinge Health. "The journey of automating healthcare delivery will be challenging, but we're excited about our momentum and are moving with haste to capture this opportunity." Second Quarter 2025 Financial Highlights: Revenue increased 55% year-over-year to $139.1 million compared to revenue of $89.8 million in Q2 2024. GAAP gross margin was 70% compared to 74% in Q2 2024. Non-GAAP gr

    8/5/25 4:05:00 PM ET
    $HNGE
    EDP Services
    Technology